Investigation of the Mutual Pharmacokinetic Interactions Between Bosentan, a Dual Endothelin Receptor Antagonist, and Simvastatin
- 1 January 2003
- journal article
- clinical trial
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 42 (3) , 293-301
- https://doi.org/10.2165/00003088-200342030-00004
Abstract
Background: In vitro, bosentan has been shown to be a mild inducer of cytochrome P450 (CYP) 2C9 and 3A4. Purpose: To investigate in vivothe mutual pharmacokinetic interactions between bosentan and...Keywords
This publication has 34 references indexed in Scilit:
- Influence of Food Intake and Formulation on the Pharmacokinetics and Metabolism of Bosentan, a Dual Endothelin Receptor AntagonistThe Journal of Clinical Pharmacology, 2002
- Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled studyThe Lancet, 2001
- Endothelins and Endothelin Receptor AntagonistsCirculation, 2000
- Recent discovery and development of endothelin receptor antagonistsExpert Opinion on Therapeutic Patents, 2000
- Induction of Drug Metabolising EnzymesClinical Pharmacokinetics, 2000
- Multiple‐Dose Pharmacokinetics, Safety, and Tolerability of Bosentan, an Endothelin Receptor Antagonist, in Healthy Male VolunteersThe Journal of Clinical Pharmacology, 1999
- The effect of bosentan on the pharmacokinetics of digoxin in healthy male subjectsPublished by Wiley ,1999
- Pharmacodynamics and Pharmacokinetics of the HMG-CoA Reductase InhibitorsClinical Pharmacokinetics, 1997
- Clinical Pharmacokinetics of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase InhibitorsClinical Pharmacokinetics, 1996
- Clinical Pharmacokinetics and Practical Applications of SimvastatinClinical Pharmacokinetics, 1993